Evidence map›Paper›PMID 39760111›Full record

ArticleMedComm2025

A SARS-CoV-2 EG.5 mRNA vaccine induces a broad-spectrum immune response in mice.

Hongyu Wang, Qinhua Peng, Xinxian Dai, Zhifang Ying, Xiaohong Wu, Xinyu Liu, Hongshan Xu, Jia Li, Leitai Shi, Jingjing Liu and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hongyu WangDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Qinhua PengDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Xinxian DaiEtiology Laboratory，National Vaccine and Serum Institute Beijing China.
Zhifang YingDivision of Respiratory Virus Vaccines National Institutes for Food and Drug Control Beijing China.
Xiaohong WuDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Xinyu LiuDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Hongshan XuDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Jia LiDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Leitai ShiDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Jingjing LiuDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Yunpeng WangDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Danhua ZhaoDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Yanqiu HuangDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Lihong YangDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Ren YangDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Guangzhi YueDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Yue SuoDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Qiang YeDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Shouchun CaoDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
Yuhua LiDepartment of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emerging of emergent SARS-CoV-2 subvariants has reduced the protective efficacy of COVID-19 vaccines. Therefore, novel COVID-19 vaccines targeting these emergent variants are needed. We designed and prepared CoV072, an mRNA-based vaccine against SARS-CoV-2 Omicron (EG.5) and other emergent SARS-CoV-2 subvariants that encodes the EG.5 spike protein. Six-week-old female BALB/C mice were used to assess humoral and cellular immune responses and cross-reactive neutralizing activity against various SARS-CoV-2 subvariants. Meanwhile different immunization strategies and doses were performed to detect the immunogenicity of this mRNA vaccine. Our results show that two doses of 5 µg CoV072 or a single dose of 15 µg CoV072 both induced broad-spectrum cross-protection ability in mice. Compared with a single dose of 15 µg CoV072, two doses of 5 µg COV072 exhibited higher levels of pseudovirus neutralizing antibody (PNAb) and cross-reactive IgG responses to multiple variants. Moreover, higher levels of neutralizing antibody (NAb) against live XBB and EG.5 variants were also induced. Th1-biased cellular immune response was induced in all vaccination groups. The antigen design and immunization strategy of this study have reference significance for the research of the next generation of COVID-19 vaccine and other vaccines.

Indexed as

immunization strategiesimmunogenicitymRNA‐based vaccinesSARS‐CoV‐2 variants

Identifiers

PMID39760111
PMCPMC11695206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.